Thierry Laugel
President chez Argobio SAS
Provenance du réseau au premier degré de Thierry Laugel
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.
21
| Holding Company | Investment Managers | 21 |
Eurazeo Investment Manager - EIM SA
 Eurazeo Investment Manager - EIM SA Investment ManagersFinance Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.
17
| Holding Company | Investment Managers | 17 |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.
11
| Holding Company | Biotechnology | 11 |
Orano Med SAS
 Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.
7
| Subsidiary | Biotechnology | 7 |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Meiogenix SAS
 Meiogenix SAS BiotechnologyHealth Technology Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.
6
| Holding Company | Biotechnology | 6 |
| Public Company | Medical Specialties | 6 | |
PathoQuest SAS
 PathoQuest SAS Medical SpecialtiesHealth Technology PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.
5
| Holding Company | Medical Specialties | 5 |
BliNK Biomedical SAS
 BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.
2
| Holding Company | Biotechnology | 2 |
Argobio SAS
 Argobio SAS Miscellaneous Commercial ServicesCommercial Services Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Kurma Biofund FCPR
 Kurma Biofund FCPR Investment ManagersFinance Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million.
1
| Venture Capital Fund | Investment Managers | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Thierry Laugel via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Ecole Polytechnique | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Graduate Degree | |
| CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member Director/Board Member | |
| ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
Corlieve Therapeutics SAS
 Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Emergence Therapeutics AG
 Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| Université Catholique de Louvain | College/University | Doctorate Degree Doctorate Degree | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | President Chief Tech/Sci/R&D Officer | |
Key Neurosciences SAS
 Key Neurosciences SAS Miscellaneous Commercial ServicesCommercial Services Key Neurosciences SAS provides research and development services. Its services include product and technology development, fund raising, business and commercial development, and project management. The company was founded in December 2010 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Founder | |
| Universite Paris Cite | College/University | Doctorate Degree Doctorate Degree | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman | |
Tc Land Expression SA
 Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| University of Orsay | College/University | Graduate Degree Graduate Degree | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| THERADIAG | Medical Specialties | Director/Board Member Director/Board Member | |
Orano Recyclage SAS
 Orano Recyclage SAS Miscellaneous Commercial ServicesCommercial Services Orano Recyclage SAS engages in the production and transformation of nuclear materials. The company is based in La Hague, France. The French company is ultimately controlled by the Government of France. | Miscellaneous Commercial Services | Chairman Chief Executive Officer | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Orano Cycle SA
 Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | Other Metals/Minerals | Chief Executive Officer Director/Board Member | |
| Ecole Supérieure de Commerce de Toulouse | College/University | Graduate Degree Undergraduate Degree | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| INTEGRAGEN | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| Sorbonne Université | College/University | Graduate Degree Graduate Degree | |
| TXCELL | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| GLOBAL BIOENERGIES | Chemicals: Specialty | Corporate Officer/Principal Director of Finance/CFO | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Chairman Director/Board Member | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member Founder | |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| GENOCEA BIOSCIENCES, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Investment Managers | Private Equity Investor Private Equity Analyst | |
Firalis SA
 Firalis SA BiotechnologyHealth Technology Firalis SA engages in the discovery and development of biomarker-based diagnostics. It offers biomarkers for drug safety, cardiovascular, inflammatory and autoimmune diseases. The firm offers a portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. The company was founded on July 8, 2008 by Hüseyin Firat and is headquartered in Huningue, France. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| AREVA | Other Metals/Minerals | Corporate Officer/Principal Chief Executive Officer | |
| Instituto de Empresa SL | College/University | Masters Business Admin Masters Business Admin | |
| MEDIAN TECHNOLOGIES | Medical/Nursing Services | Director/Board Member Chief Tech/Sci/R&D Officer | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal President |
Statistiques
Internationale
| France | 33 |
| Belgique | 7 |
| Pays-Bas | 5 |
| Espagne | 4 |
| Etats-Unis | 4 |
Sectorielle
| Health Technology | 23 |
| Consumer Services | 11 |
| Commercial Services | 8 |
| Finance | 5 |
| Health Services | 5 |
Opérationnelle
| Director/Board Member | 310 |
| Corporate Officer/Principal | 79 |
| Chairman | 76 |
| Private Equity Investor | 59 |
| Chief Executive Officer | 51 |
Relations les plus connectées
| Insiders | |
|---|---|
| Philippe Peltier | 45 |
| Russell Greig | 31 |
| Bruno Montanari | 30 |
| Khalid Islam | 29 |
| Rémi Droller | 29 |
| Anthony Adam Rosenberg | 23 |
| Franck Grimaud | 22 |
| Laurent Arthaud | 21 |
| Philippe Knoche | 21 |
| Johan Cardoen | 19 |
| Frédéric Chéreau | 17 |
| Frédéric Joël Desdouits | 16 |
| Lena Elisabeth Svanberg | 16 |
| Olivier Danos | 15 |
| Cédric Moreau | 14 |
- Bourse
- Insiders
- Thierry Laugel
- Connexions Sociétés
